LongeVC’s Post

Two words: Cancer vaccines. More words: Vaccines prolong our lives, so having vaccines for *more diseases* (like cancer) as well as *more vaccines* for existing diseases (like vaccine variants specifically for immunocompromised patients) makes us two steps closer to realistic, achievable, and healthy longevity (the kind where you don't need to be a billionaire to access it!) As always, the team at LongeVC led by Garri Zmudze (who is in Hong Kong this week talking about this!) and Sergey Jakimov has found a winner. If biotech/longevity/medtech is your thing, I recommend stalking the companies on their portfolio page or giving them a follow 👇🏻 https://lnkd.in/dFMepqVA

🧬 Introducing PentaBind Aptamer Classroom Series 2: What are Aptamers Used For? 🧬 Aptamers are single-stranded DNA or RNA molecules that bind to specific target molecules with high affinity and specificity. Since their discovery in the 1990s, aptamers have emerged as a powerful tool in biotechnology and medicine, thanks to their versatility and unique properties. At PentaBind, our current focus is on leveraging therapeutics by helping companies design aptamer drugs using Generative AI. Want to know more? Join us on our journey and explore how AI is transforming aptamer development at https://www.pentabind.com/ #Biotechnology #Aptamers #Innovation #MedicalScience #FutureOfHealthcare #TechBio #AI #Startups #DrugDiscovery #Oligos #GenerativeAI #Biotech #Community #Pharma #ArtificialIntelligence #VentureCapital #Startups #HealthcareInnovation #DrugDiscovery #Therapeutics #Diagnostics

💲 1 BILLION DOLLAR INVESTMENT 💲 Last week, Xaira Therapeutics announced their initial funding release of over $1 billion. Xaira is set to combine AI research, extensive data generation, and therapeutic product development to accelerate the delivery of effective therapies to patients. Co-founded by renowned scientists and backed by leading investors, Xaira's platform integrates cutting-edge machine learning research with comprehensive biological data sets to inform the development of novel therapeutics. Led by experienced executives, including Dr. Marc Tessier-Lavigne, the company is poised to reshape the landscape of drug discovery with its multidisciplinary approach and transformative vision. Xaira brings together three core elements: 1. Advanced machine learning research 2. Expansive data generation to power new model 3. Robust therapeutic product development. “Driven by growing data sets and new methods, there has been accelerating progress in artificial intelligence and its applications to medicine, biology and chemistry, including seminal work from David Baker’s lab at the Institute for Protein Design,” said Dr. Vikram Bajaj, CEO of Foresite Labs and Managing Director of Foresite Capital. #xairatherapeutics #xaira #funding #biotech #innovation

In today's rapidly evolving landscape, Biotechs stand out as a beacon of innovation and potential for investors. The realm of biotechnology offers a unique blend of groundbreaking scientific advancements and promising investment opportunities. As we navigate the current investment environment, Biotechs continue to attract attention due to their potential to revolutionize healthcare, agriculture, and beyond. The fusion of biology and technology not only drives scientific progress but also presents lucrative prospects for those keen on investing in the future. With ongoing developments in gene editing, personalized medicine, and biopharmaceuticals, the Biotech sector remains dynamic and full of promise. Investors looking to diversify their portfolios and tap into transformative technologies are increasingly turning their focus towards Biotechs. Amidst this backdrop, staying informed about the latest trends, breakthroughs, and regulatory updates is key to making informed investment decisions in the Biotech space. Whether you're a seasoned investor or someone exploring new avenues, keeping a pulse on Biotechs can unveil exciting opportunities for growth and impact. Let's embrace the potential of Biotechs together and pave the way for a future where science, innovation, and investments converge to shape a better tomorrow. #Biotech #Investments #Innovation #FutureProofInvesting

In the #biotech sector, data integration is becoming just as crucial as breakthrough discoveries. And it's creating an incredible future! We're seeing remarkable progress in personalized treatments and accelerated #drugdiscovery. Companies are producing tangible results for treating previously intractable conditions. As an #investor, these are all attractive, exciting biotech advancements. But remember to balance that enthusiasm with research, clinical validation, and clear-headed decisions! https://loom.ly/qwUgiTA

Very much looking forward to this discussion. Delivering the promises of #ai in #drugdiscovery will involve a lot of reality check on real value inflection points, collaboration agreements frameworks and overall market needs that will be debated on this afternoon. For those curious or involved in delivering technologies for life sciences at scale #techbio, the link to register is here: https://lnkd.in/exAQzcG5

Latest DON Therapeutics News In today's dynamic healthcare landscape, biotechnology is revolutionizing the practice and perception of medicine. This industry is spearheading innovations in personalized medicine and drug development significantly enhancing patient care and addressing global health challenges. Biotechnology, with its roots in biological sciences, is unlocking new possibilities in disease treatment and prevention. By harnessing the power of genomics, proteomics, and advanced biomanufacturing techniques, biotech companies are developing targeted therapies that are tailored to the individual genetic profiles of patients. This personalized approach not only increases the efficacy of treatments but also minimizes adverse effects, leading to better patient outcomes. Moreover, biotechnology is playing a crucial role in drug development. The traditional drug development process, often lengthy and costly, is being transformed by biotechnological advancements. Techniques such as CRISPR gene editing and advanced bioinformatics are enabling faster and more precise development of new therapeutics. This acceleration in drug discovery is crucial in responding to emerging health threats and managing chronic diseases more effectively. More about DON Therapeutics: https://lnkd.in/eKs-9g9e We are always looking for new healthcare opportunities. Submit your opportunity: https://lnkd.in/dJfhwVvv #funding #biotechnology #medtech #startups #investors

 🔆 Exciting News for Investors in Biotech Innovation! 🔆 We are thrilled to share a major milestone for FUTR BIO, where innovation meets impact in biotech. Our recent proof-of-concept preclinical data demonstrates compelling results: our mRNA vaccine platform delivers robust protection at low doses, promising long-term safety and efficacy. This breakthrough underscores our commitment to revolutionizing healthcare through synthetic biology. Learn more about our groundbreaking approach: https://futr.bio/ Why Invest in FUTR BIO?  ✨Advanced Technology: Harnessing synthetic biology to pioneer next-gen therapies.  ✨Market Potential: Addressing critical medical needs with scalable solutions.  ✨Proven Results: Exciting preclinical data supports vaccine effectiveness and safety. ✨ Experienced Team: Led by a passionate team of industry experts and visionaries. We invite visionary investors to join us in shaping the future of biotechnology. Let’s collaborate to bring these transformative solutions to the global stage. Curious to learn more about our journey? Let's connect and explore how you can contribute to the FUTR BIO vision! #BiotechInnovation #HealthcareRevolution #InvestInFutrBio #SyntheticBiology #StartupInvestment #HealthTech

AI has embedded itself in every aspect of our technology and society. Biological research and, in particular, drug discovery is no different in this respect, and it is already apparent that AI will have a hugely positive impact in shortening drug discovery timelines and improving the chances of success in identifying life-saving and life-changing drugs. The potential is huge. And so are the challenges. Frequently, progress in this sector is based on collaborations between companies in the tech and biotech/pharma spaces. However, this often involves very different-sized companies with different outlooks and strategies when it comes to IP, commercial agreements, and regulation. This has the potential to create challenges for both sides. Join us and our panel of experts for an afternoon seminar where we will take a look at the challenges that arise when tech meets bio and a discussion on how we can solve them. Our speakers: Alexander Korenberg, Kilburn & Strode Sarah Lau, Kilburn & Strode Daniel Pavin, Covington Uzma Choudry, Ph.D, Octopus Ventures Liz Elmhirst, Achilles Therapeutics Aline Charpentier, Bruntwood SciTech Jason Rice, GSK Anne Poupon, MAbSilico We hope you can join us! Register here: https://lnkd.in/exAQzcG5